Privia Health
PRVA
90 hedge funds and large institutions have $2.52B invested in Privia Health in 2021 Q2 according to their latest regulatory filings, with 90 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
53.76% more ownership
Funds ownership: 0% → 53.76% (+54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$1.13B |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$243M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$104M |
| 4 |
BlackRock
New York
|
+$90.7M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$48M |
Top Sellers
PRVA Hedge Fund Activity: Q2 2021 in Review
90 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Privia Health (PRVA) for Q2 2021, worth a combined $2.52B.
Buyers outnumbered sellers: 90 funds opened new PRVA positions and 0 closed out — a net gain of 90 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $1.13B.
- 90 institutional investors held Privia Health (PRVA) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $2.52B of Privia Health stock for Q2 2021.
- 90 funds opened new Privia Health positions in Q2 2021 and 0 closed out, a net change of +90 holders.
- The largest Privia Health buyer in Q2 2021 was Goldman Sachs, an estimated $1.13B added.
Based on aggregated 13F filings for Q2 2021.